Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ofloxacin is eliminated unchanged renally by glomerular filtration and active tubular secretion. However, caution should be exercised as both drugs have possible risks of QT prolongation and/or TdP on the CredibleMeds.org website.
Particular caution must be used when prescribing Kaletra and medicinal products known to induce QT interval prolongation. Indeed, Kaletra could increase concentrations of the co-administered medicinal products and this may result in an increase of their associated cardiac adverse events. Cardiac events have been reported with Kaletra in preclinical studies; therefore, the potential cardiac effects of Kaletra cannot be currently ruled out. Kaletra Summary of Product Characteristics, AbbVie Ltd, January 2021.
View all available interactions with
Lopinavir/ritonavir (LPV/r) by clicking